NasdaqGS:KPTI

Stock Analysis Report

Executive Summary

Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases.

Rewards

Trading at 53.2% below its fair value

Revenue is forecast to grow 50.14% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Karyopharm Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KPTI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.4%

KPTI

0.8%

US Biotechs

1.3%

US Market


1 Year Return

76.8%

KPTI

16.4%

US Biotechs

19.4%

US Market

Return vs Industry: KPTI exceeded the US Biotechs industry which returned 16.4% over the past year.

Return vs Market: KPTI exceeded the US Market which returned 19.4% over the past year.


Shareholder returns

KPTIIndustryMarket
7 Day4.4%0.8%1.3%
30 Day12.7%8.9%2.6%
90 Day54.2%16.0%5.0%
1 Year76.8%76.8%17.4%16.4%22.0%19.4%
3 Year74.4%74.4%27.2%23.0%46.8%37.3%
5 Year-55.9%-55.9%4.6%-0.5%66.3%48.0%

Price Volatility Vs. Market

How volatile is Karyopharm Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Karyopharm Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KPTI ($17.01) is trading below our estimate of fair value ($36.32)

Significantly Below Fair Value: KPTI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KPTI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: KPTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KPTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KPTI is overvalued based on its PB Ratio (17.8x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Karyopharm Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

50.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KPTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KPTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KPTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KPTI's revenue (50.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: KPTI's revenue (50.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KPTI is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Karyopharm Therapeutics performed over the past 5 years?

-18.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KPTI is currently unprofitable.

Growing Profit Margin: KPTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KPTI is unprofitable, and losses have increased over the past 5 years at a rate of -18.7% per year.

Accelerating Growth: Unable to compare KPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KPTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: KPTI has a negative Return on Equity (-349.35%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Karyopharm Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: KPTI's short term assets ($280.9M) exceed its short term liabilities ($39.2M).

Long Term Liabilities: KPTI's short term assets ($280.9M) exceed its long term liabilities ($198.7M).


Debt to Equity History and Analysis

Debt Level: KPTI's debt to equity ratio (180.3%) is considered high.

Reducing Debt: Insufficient data to determine if KPTI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: KPTI has a low level of unsold assets or inventory.

Debt Coverage by Assets: KPTI's debt is covered by short term assets (assets are 2.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KPTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KPTI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Karyopharm Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate KPTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KPTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KPTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KPTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KPTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Karyopharm Therapeutics's salary, the management and board of directors tenure and is there insider trading?

4.9yrs

Average management tenure


CEO

Michael Kauffman (56yo)

8.9yrs

Tenure

US$2,274,945

Compensation

Dr. Michael G. Kauffman, M.D., Ph.D. serves as Advisor at Prime Movers Lab and co-founded Karyopharm Therapeutics Inc. in 2008 and has been its Chief Executive Officer since January 05, 2011. Dr. Kauffman  ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD2.27M) is about average for companies of similar size in the US market ($USD2.63M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.9yrs

Average Tenure

50yo

Average Age

Experienced Management: KPTI's management team is considered experienced (4.9 years average tenure).


Board Age and Tenure

5.6yrs

Average Tenure

56yo

Average Age

Experienced Board: KPTI's board of directors are considered experienced (5.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$619,11405 Mar 19
Wiaczeslaw Smolokowski
EntityIndividual
Shares149,624
Max PriceUS$4.14
SellUS$7,127,92428 Feb 19
Wiaczeslaw Smolokowski
EntityIndividual
Shares1,481,643
Max PriceUS$5.00

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.8%.


Management Team

  • Michael Kauffman (56yo)

    Co-Founder

    • Tenure: 8.9yrs
    • Compensation: US$2.27m
  • Sharon Shacham (49yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$2.09m
  • Cameron Peters (59yo)

    Vice President of Finance

    • Tenure: 0.9yrs
  • Mansoor Mirza (58yo)

    Clinical Consultant

    • Tenure: 0yrs
    • Compensation: US$367.59k
  • Mike Mason (44yo)

    Senior VP

    • Tenure: 0.8yrs
  • Chris Primiano (38yo)

    Executive VP

    • Tenure: 5.8yrs
    • Compensation: US$1.52m
  • Ran Frenkel (50yo)

    Chief Development Operations Officer

    • Tenure: 4.9yrs
    • Compensation: US$6.48m
  • Ian Karp

    Vice President of Investor & Public Relations

    • Tenure: 1.4yrs
  • Tina Beamon

    Chief Compliance Officer

    • Tenure: 0.6yrs
  • Perry Monaco

    Senior Vice President of Sales

    • Tenure: 0yrs

Board Members

  • Deepa Pakianathan (54yo)

    Independent Director

    • Tenure: 6.7yrs
    • Compensation: US$274.37k
  • Michael Kauffman (56yo)

    Co-Founder

    • Tenure: 8.9yrs
    • Compensation: US$2.27m
  • Garen Bohlin (72yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$278.59k
  • Barry Greene (56yo)

    Lead Independent Director

    • Tenure: 4.9yrs
    • Compensation: US$312.12k
  • Mikael Dolsten (60yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$266.59k
  • Sharon Shacham (49yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$2.09m
  • Mansoor Mirza (58yo)

    Clinical Consultant

    • Tenure: 0yrs
    • Compensation: US$367.59k
  • Giulio Draetta

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • J. Garland (50yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: US$280.59k
  • Chris Kirk (47yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Karyopharm Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Karyopharm Therapeutics Inc.
  • Ticker: KPTI
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.068b
  • Shares outstanding: 62.79m
  • Website: https://www.karyopharm.com

Number of Employees


Location

  • Karyopharm Therapeutics Inc.
  • 85 Wells Avenue
  • 2nd Floor
  • Newton
  • Massachusetts
  • 2459
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KPTINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2013
25KDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2013

Biography

Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets f ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 00:14
End of Day Share Price2019/12/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.